Presentation
10 June 2024 Spectral imaging advances: FDA's regulatory research on photon counting detector systems
Author Affiliations +
Abstract
The advent of photon-counting detectors (PCDs) promises a significant shift in clinical x-ray imaging by capturing individual x-ray photon's intensity and energy, unlike traditional detectors. This enables energy discrimination, which has the potential to improve image quality, reduce radiation dose, and enable new diagnostic applications. PCDs can significantly improve spectral x-ray imaging systems for tissue characterization and material separation, paving the way for CT color and quantitative imaging. Most major CT companies have recently been developing prototype PCD CT systems. Two CT systems incorporating a PCD were FDA cleared within the last two years. Furthermore, PCDs empower novel acquisition techniques beyond conventional x-ray transmission, including coherent scatter and phase contrast imaging. This abstract outlines key advancements in spectral imaging via PCDs, emphasizing studies and assessments conducted at the FDA's Office of Science and Engineering Laboratories (OSEL) and Division of Imaging, Diagnostics, and Software Reliability (DIDSR). The focus is on the transformative potential of PCD-equipped spectral x-ray systems in enhancing diagnostic imaging.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Bahaa Ghammraoui "Spectral imaging advances: FDA's regulatory research on photon counting detector systems", Proc. SPIE 13043, Anomaly Detection and Imaging with X-Rays (ADIX) IX, 1304304 (10 June 2024); https://doi.org/10.1117/12.3014611
Advertisement
Advertisement
KEYWORDS
Imaging systems

Imaging spectroscopy

Photon counting

X-ray imaging

Coherence imaging

Diagnostics

Photodetectors

Back to Top